At Mays Cancer Center at UT Health San Antonio, we are revolutionizing cancer care through breakthrough research, cutting-edge treatments and a deep commitment to saving lives. Our work doesn’t stop in the lab—we bring discoveries to the patient’s bedside, ensuring the latest advancements in cancer care are accessible to those who need them most. With a multidisciplinary team of experts, we provide best-in-class therapies, giving patients and their families hope, healing and life-changing support every step of the way.
As the only National Cancer Institute (NCI)-designated Cancer Center in South Texas, the Mays Cancer Center serves a vast 38-county region with over 5 million residents. Our team of more than 300 cancer researchers and clinicians is dedicated to transforming the way cancer is diagnosed, treated and prevented—not just in San Antonio and South Texas, but worldwide.
Our 175+ active clinical trials offer patients groundbreaking new treatment options.
Pioneering Pediatric Cancer Research
The Greehey Children’s Cancer Research Institute at UT Health San Antonio is one of only two institutes in the U.S. exclusively dedicated to pediatric cancer research. Home to more than a dozen laboratories, the institute is at the forefront of cancer genomics, DNA repair, RNA biology and drug development—all with the goal of creating safer, more effective and less toxic treatments for childhood cancers.
At UT Health San Antonio, we are more than a cancer center—we are a beacon of hope, a hub of innovation and a leader in the fight against cancer.
Join us in the fight. Together, we are making a difference!
Only National Cancer Institute-designated cancer center in South Texas
300+ cancer researchers and clinicians
World-renowned Breast Cancer Symposium
In The News
Like a busy restaurant kitchen, our cells depend on well-organized working spaces to assemble the “recipes” that keep the body healthy. UT San Antonio scientist, David Libich, PhD, recently received a five-year, $2.1 million Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences to study how certain proteins form these organizational hubs and what happens when things do not go according to plan.
Scientists at The University of Texas at San Antonio (UT San Antonio) are investigating a major immune system pathway that leads to the development of chronic pain and a drug that has the potential to stop the process in its tracks. Their study, published April 22 in Cell Reports, is the first of its kind to show a path toward the prevention of chronic pain.
Written by: Claire Kowalick More than 70% of cancers — including breast, bladder, cervical and lung cancer — show evidence of mutations linked to a group of enzymes called apolipoprotein B mRNA-editing enzyme catalytic polypeptides, or APOBEC. “APOBEC mutagenesis is the second-largest source of mutation in cancer and, importantly, the largest one we can do […]